Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
|Articles|September 14, 2018
Avara Acquires Sterile Manufacturing Facility from Sandoz
Author(s)BioPharm International Editors
Avara Pharmaceutical Services acquired Sandoz’s sterile manufacturing facility for injectable medicines in Boucherville, Quebec, Canada.
Advertisement
On Sept. 6, 2018, contract development and manufacturing organization Avara Pharmaceutical Services announced that it acquired Sandoz’s sterile manufacturing facility for injectable medicines in Boucherville, Quebec, Canada.
The Boucherville site provides a number of pharmaceuticals to the Canadian healthcare system, mostly hospitals. As part of the asset purchase agreement, the companies signed a long-term supply contract to guarantee continuous supply of products manufactured in Boucherville. Avara reports that there will be no impact on jobs and Avara intends to invest in the site and pursue business development opportunities to optimize the plant’s utilization and expand its client base.
The acquisition of the sterile manufacturing facility,
The Sandoz facility acquisition is the most recent in a series of site purchases by Avara. Other facilities acquired by Avara include another sterile facility in
“This acquisition represents an important addition to the Avara portfolio and further expands our sterile processing capability, which is in very high demand,” said Timothy C. Tyson, chairman and CEO, in a company press release. “It comes with a market leading development capability and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements. We are excited to transition this Sandoz world-class center of excellence into a world-class center of excellence for the contract development manufacturing market.”
The Boucherville acquistion brings Avara’s total number of manufacturing and development sites to 10: two in Canada; three in the United States, including corporate headquarters; one in Puerto Rico; one in the UK; one in Ireland; one in Italy; and one in France.
Source:
Advertisement
Related to this article
Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
Vironexis Biotherapeutics reported that the first three antibody-naive patients with relapsed/refractory acute lymphoblastic leukemia treated with its one-time in vivo immunotherapy VNX-101 all achieved MRD-negative complete responses, with durability tracked through at least nine months.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
IMVT-1402 (imeroprubart) failed to reach statistical significance on CLASI-A at Week 12 in a 57-patient proof-of-concept study, and Immunovant will stop development in cutaneous lupus erythematosus. The anti-FcRn antibody continues in five other autoimmune indications.
SOTIO Biotech's LRRC15-targeted antibody-drug conjugate SOT106 now holds both Orphan Drug and Fast Track Designations in soft tissue sarcoma and osteosarcoma. The company expects to start first-in-human testing later in 2026.
Advertisement
Advertisement